By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Researchers detail new data in Biotechnology. According to news originating from Austin, Texas, by NewsRx correspondents, research stated, "Helper-dependent adenoviral (HD-Ad) vectors have great potential for gene therapy applications; however, their administration induces acute toxicity that impairs safe clinical applications. We previously observed that PEGylation of HD-Ad vectors strongly reduces the acute response in murine and primate models."
Our news journalists obtained a quote from the research from the University of Texas, "To evaluate whether PEGylated HD-Ad vectors combine reduced toxicity with the correction of pathological phenotypes, we administered an HD-Ad vector expressing the human apolipoprotein A-I (hApoA-I) to low-density lipoprotein (LDL)-receptor-deficient mice (a model for familial hypercholesterolemia) fed a high-cholesterol diet. Mice were treated with high doses of HD-Ad-expressing apo A-I or its PEGylated version. Twelve weeks later, LDL levels were lower and high-density lipoprotein (HDL) levels higher in mice treated with either of the vectors than in untreated mice. After terminal killing, the areas of atherosclerotic plaques were much smaller in the vector-treated mice than in the control animals. Moreover, the increase in pro-inflammatory cytokines was lower and consequently the toxicity profile better in mice treated with PEGylated vector than in mice treated with the unmodified vector. This finding indicates that the reduction in toxicity resulting from PEGylation of HD-Ad vectors does not impair the correction of pathological phenotypes."
According to the news editors, the research concluded: "It also supports the clinical potential of these vectors for the correction of genetic diseases."
For more information on this research see: PEGylated helper-dependent adenoviral vector expressing human Apo A-I for gene therapy in LDLR-deficient mice. Gene Therapy, 2013;20(12):1124-1130. Gene Therapy can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Gene Therapy - www.nature.com/gt/)
The news correspondents report that additional information may be obtained from E. Leggiero, Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712, United States. Additional authors for this research include D. Astone, V. Cerullo, B. Lombardo, C. Mazzaccara, G. Labruna, L. Sacchetti, F. Salvatore, M. Croyle and L. Pastore (see also technology.html">Biotechnology).
Keywords for this news article include: Biotechnology, Texas, Austin, Gene Therapy, United States, Bioengineering, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC